Effect of Rifampicin on the Pharmacokinetics of a Single Oral Dose of BI 894416 in Healthy Male Subjects (an Open-label, One-way Crossover Study)
Latest Information Update: 16 Aug 2023
At a glance
- Drugs BI 894416 (Primary) ; Rifampicin
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 22 Oct 2019 Status changed from active, no longer recruiting to completed.
- 07 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 17 Sep 2019 Status changed from not yet recruiting to recruiting.